• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Daiichi Sankyo Ltd (OP: DSKYF )

    38.56 UNCHANGED
    Streaming Delayed Price Updated: 10:23 AM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 250
    Open 38.56
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 38.56
    Today's Range 38.56 - 38.56
    52wk Range 23.45 - 44.64
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront
    Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones. 
    Via Talk Markets
    Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
    "As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say. 
    Via Benzinga

    Performance

    YTD
    +46.50%
    +46.50%
    1 Month
    +7.86%
    +7.86%
    3 Month
    +5.15%
    +5.15%
    6 Month
    +18.06%
    +18.06%
    1 Year
    +37.86%
    +37.86%

    More News

    Read More
    Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
    Via Benzinga
    Exposures Product Safety
    FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
    Via Benzinga
    Exposures Product Safety
    5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
    Via Benzinga
    Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
    Via Benzinga
    Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
    Via Benzinga
    Why Is AstraZeneca Stock Trading Lower On Tuesday?
    Via Benzinga
    Double Good News For AstraZeneca's Breast Cancer Drugs
    Via Benzinga
    AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
    Via Benzinga
    Exposures Product Safety
    What's Going On With Pfizer Stock Today?
    Via Benzinga
    Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
    Via Benzinga
    Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
    Via Benzinga
    AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
    Via Benzinga
    FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
    Via Benzinga
    AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
    Via Benzinga
    AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
    Via Benzinga
    AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
    Via Benzinga
    European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
    Via Benzinga
    With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
    Via Benzinga
    Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
    Via Benzinga
    AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
    Via Benzinga
    Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
    Via Benzinga
    AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
    Via Benzinga
    The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.